| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | BB2; CD54; P3.58 |
| WB Predicted band size | 58 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ICAM1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ICAM1抗体的3-4篇代表性文献的简要信息(基于公开研究领域归纳，非特定真实论文)：
1. **文献名称**：*"Targeting ICAM1 in tumor-associated vasculature enhances T cell-mediated cancer immunotherapy"*
**作者**：Smith A, et al.
**摘要**：研究证明，抗ICAM1抗体通过靶向肿瘤血管内皮细胞上的ICAM1.促进T细胞浸润肿瘤微环境，显著增强免疫检查点抑制剂的抗肿瘤效果。
2. **文献名称**：*"ICAM1 blockade reduces monocyte adhesion and atherosclerosis progression in mice"*
**作者**：Zhang Y, et al.
**摘要**：该文献利用抗ICAM1抗体抑制单核细胞与血管内皮的黏附，在动脉粥样硬化小鼠模型中观察到斑块形成减少和炎症反应缓解。
3. **文献名称**：*"Anti-ICAM1 antibodies attenuate acute lung injury by limiting neutrophil infiltration"*
**作者**：Kishimoto TK, et al.
**摘要**：通过动物模型发现，阻断ICAM1可减少中性粒细胞向肺组织的迁移，从而减轻内毒素诱导的急性肺损伤和炎症反应。
4. **文献名称**：*"ICAM1 as a receptor for viral entry: implications for antibody-based therapeutics"*
**作者**：Chen L, et al.
**摘要**：研究发现某些病毒(如鼻病毒)利用ICAM1作为宿主细胞入侵受体，抗ICAM1抗体可竞争性抑制病毒结合，为抗病毒感染提供新策略。
(注：以上内容为领域研究方向的概括性示例，具体文献需通过数据库如PubMed检索确认。)
ICAM-1 (Intercellular Adhesion Molecule 1), also known as CD54. is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It plays a critical role in mediating leukocyte adhesion and transmigration during inflammatory responses by binding to integrins like LFA-1 (lymphocyte function-associated antigen 1) on immune cells. ICAM-1 is constitutively expressed at low levels on endothelial cells, epithelial cells, and certain immune cells but is markedly upregulated under inflammatory conditions (e.g., cytokines like TNF-α or IFN-γ) or pathological states such as autoimmune diseases, infections, and cancer.
ICAM-1 antibodies are tools designed to target and modulate ICAM-1 activity. In research, they are widely used to block ICAM-1/LFA-1 interactions in vitro or in animal models to study leukocyte trafficking, inflammation, or tumor microenvironment regulation. Therapeutic applications are also being explored; for example, anti-ICAM-1 agents may inhibit excessive immune activation in autoimmune disorders or reduce cancer metastasis by disrupting cell adhesion. However, most ICAM-1-targeting therapies remain in preclinical or early clinical stages. Additionally, ICAM-1 antibodies serve as diagnostic markers in diseases where endothelial activation or immune dysregulation is implicated. Challenges include optimizing specificity and delivery, as systemic inhibition of ICAM-1 may impair normal immune surveillance. Overall, ICAM-1 antibodies are pivotal in elucidating immune mechanisms and developing targeted therapies.
×
